FULC

Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics, Inc. (FULC) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (D). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
D
Factor Score 1.4 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -6.8
EV / EBITDA 0.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 0.8%
Price Return 12M -51.2%
Catalyst Signal 0.00
Market Cap $285.7M
TTM Revenue N/A
Price / Sales N/A
ROE -32.4%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B+ (3.7) C- (2.1) D (1.4) C- (2.1) C+ (2.6) C (2.4)
2026-11-05 A- (3.9) C- (2.1) D (1.4) C- (2.1) C+ (2.7) C (2.4)
2026-10-29 B+ (3.7) C- (2.1) D (1.4) C- (2.0) C+ (2.7) C (2.3)
2026-10-22 B+ (3.7) C- (2.0) D (1.4) C- (1.9) C+ (2.6) C (2.3)
2026-10-15 B+ (3.7) C- (2.0) D (1.4) C- (2.0) C+ (2.6) C (2.4)
Page 1 of 7